期刊文献+

基于蒙特卡洛模拟法优化米诺环素的给药方案 被引量:6

Optimum Dosage Regimen of Minocycline Based on Monte Carlo Simulation
下载PDF
导出
摘要 目的:利用蒙特卡洛模拟法计算米诺环素在不同给药剂量下(单剂量静滴50,100和200mg)AUC/ MIC值概率分布。方法:收集已发表的米诺环素的药动学资料和解脲脲原体对该抗生素的MIC分布数据,利用Crystal Ball软件模拟5 000个"患者"的治疗试验,求算出每个"患者"的AUC/MIC值及其概率分布,进而找出最佳治疗方案。结果:米诺环素在高、中、低3种给药剂量下均能取得较好的治疗效果,AUIC达到有效治疗指标(AUIC≥25 h)的概率分别为高(100%)、中(100%)和低(99.09%)。结论:蒙特卡洛模拟法把药动学和药效学结合起来,既考虑了不同个体对药物处置的差异性,又考虑了病原菌耐药性的差异,这样获得的给药方案将更合理,也更能提高临床治疗效果。 Objective: This study evaluated the AUC/MIC ratios for minocycline which was administered with different dosages against Ureaplasma urealyticum using a Monte Carlo simulation. Methods: Pharmacokinetic data and 49 MIC distributions against Ureaplasma urealyticum were obtained from the studies in healthy volunteers published in the literature. Monte Carlo simulation of 5 000 patients was done to attain the probability and frequency of each AUC/MIC ratio and the best dosage regiment was chosen. Results: 100%, 100% and 99.09% of the 5 000 patients treated with minocycline using the three dosage regiments attained a good pharmacodynamic target, respectively. Conclusion: Designing of dosage regimen based on Monte Carlo simulation is reasonable and valid, because this method has taken the differences between individuals into full account.
作者 杨帆
出处 《抗感染药学》 2009年第2期96-100,共5页 Anti-infection Pharmacy
关键词 蒙特卡洛模拟法 米诺环素 解脲脲原体 给药方案 Monte Carlo simulation minocycline ureaplasma urealyticum dosage regimen
  • 相关文献

参考文献3

二级参考文献8

  • 1钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量:581
  • 2[1]Martinez,Maria A,Ovalle,et al.Occurrence and antimicrobial susceptibility of Ureaplasma parvum (Ureaplasma urealyticum biovar 1)and Ureaplasma urealyticum(Ureaplasma urealyticum biovar 2) from patients with adverse pregnancy outcomes and normal pregnant women[J].Scan J Infec Dis,2001,33(8):604-610.
  • 3[4]Blanchard A,Crabb D W,Dybvig K,et al.Rapid detection of tetM in Mycoplasma hominis and Ureaplasma urealyticum by PCR,tetM confers resistance to tetracycline but not necessarily to doxycycline[J].FEMS Microbiol lett,1992,74(2-3):277-281.
  • 4[5]Bebear C M,Renaudin H,Charron A,et al.DNA gyrase and topoisomerase 1V mutatutions in clinical isolates of Ureaplasma spp.and Mycoplasma horninis resistant to fluoroquinolones[J].Antimicnob Agents Chemother,2003,47(10):3323-3325.
  • 5MASCHER HJ. Determination of minocycline in human plasma by high-performance liquid chromatography with UV detection after liquid-liquid extraction [ J 1. J Chromatogr A, 1998,812 ( 1 ) : 339 - 342.
  • 6ORTI V, AUDRAN M, GIBERT P, et al. High-performance liquid chromatographic assay for minocycline in human plasma and parrotid Saliva[ J ]. J Chromatogra B,2000,738 (2) :357 - 365.
  • 7宋庆翠,汤震,仇益群.米诺环素胶囊对人体相对生物利用度的研究[J].中国药业,2001,10(2):27-28. 被引量:7
  • 8张艳,吴移谋,余敏君,尹卫国.解脲支原体药敏与tetM基因检测及生物群的研究[J].中国皮肤性病学杂志,2001,15(1):4-6. 被引量:13

共引文献12

同被引文献103

引证文献6

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部